Veracyte Announces First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 4% as Trump says US reinstating Iran naval blockade
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Veracyte, Inc (VCYT) PT Lowered to $26 at Needham & Company
May 4, 2022 6:51 AM EDTNeedham & Company analyst Mike Matson lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $26.00 (from $31.00) while maintaining a Buy rating following earnings.
The analyst commented, "VCYT's 1Q22 revenue and EPS beat consensus. Organic revenue growth (excluding estimated revenue from Decipher and... More
Veracyte (VCYT) Tops Q1 EPS by 4c
May 3, 2022 4:40 PM EDTVeracyte (NASDAQ: VCYT) reported Q1 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $67.8 million versus the consensus estimate of $62.32 million.
GUIDANCE:
Veracyte sees FY2022 revenue of $265-275 million, versus the consensus of $270... More
